AllianceBernstein
NGNE icon

AllianceBernstein’s Neurogene NGNE Stock Holding History

AllianceBernstein’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
13,770
+3,200
+30% +$88.1K ﹤0.01% 3017
2026
Q1 		$218K Hold
10,570
– – ﹤0.01% 3014
2025
Q4 		$218K Hold
10,570
– – ﹤0.01% 3037
2025
Q3 		$183K Hold
10,570
– – ﹤0.01% 3103
2025
Q2 		$158K Buy
+10,570
New +$166K ﹤0.01% 3102
2024
Q4 		– Sell
-65,119
Closed -$2.73M – 3241
2024
Q3 		$2.73M Buy
+65,119
New +$2.53M ﹤0.01% 1810
2022
Q2 		– Sell
-1,125
Closed -$42K – 3337
2022
Q1 		$42K Sell
1,125
-130
-10% -$7.58K ﹤0.01% 3185
2021
Q4 		$121K Sell
1,255
-65
-5% -$7.92K ﹤0.01% 3170
2021
Q3 		$191K Hold
1,320
– – ﹤0.01% 3099
2021
Q2 		$244K Buy
1,320
+210
+19% +$46.5K ﹤0.01% 3091
2021
Q1 		$273K Sell
1,110
-115
-9% -$29.4K ﹤0.01% 2941
2020
Q4 		$345K Hold
1,225
– – ﹤0.01% 2789
2020
Q3 		$294K Buy
1,225
+280
+30% +$67.8K ﹤0.01% 2820
2020
Q2 		$314K Buy
+945
New +$246K ﹤0.01% 2856

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

AllianceBernstein's NGNE Position: Q2 2026 in Review

AllianceBernstein increased its Neurogene (NGNE) stake by 30% in Q2 2026, buying an estimated $88.1K and bringing the position to 13,770 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #3017.

AllianceBernstein first reported a position in NGNE in Q2 2020 and has held it in 14 quarters since. The position peaked at $2.73M in Q3 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • AllianceBernstein held 13,770 shares of Neurogene worth $278K as of Q2 2026.
  • AllianceBernstein bought 3,200 Neurogene shares in Q2 2026, an estimated $88.1K.
  • Neurogene made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3017 holding.
  • AllianceBernstein first reported a position in Neurogene in Q2 2020 and has held it in 14 quarters since.
  • AllianceBernstein's Neurogene position peaked at $2.73M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.